4 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow afuresertib: new trials by email Literature Review of afuresertib trials Research Report on afuresertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Afuresertib, Nab paclitaxel, Docetaxel - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Laekna Limited | 22 | 2022-07-01 | 2025-11-17 |
| Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Paclitaxel, Afuresertib - Platinum-resistant Ovarian Cancer | Phase 2 | Completed | Laekna Limited | 150 | 2020-07-07 | 2026-10-19 |
| Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase I and Phase II: LAE001/prednisone + afuresertib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Laekna Limited | 49 | 2019-09-13 | 2024-10-10 |
| Continuation Study of the Oral AKT Inhibitor GSK2110183 GSK2110183 (afuresertib) - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 11 | 2012-02-08 | 2019-07-09 |
Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Neoplasms (1) · Uterine Cervical Neoplasms (1)
Laekna Limited (3) · Novartis Pharmaceuticals (1)
United States (3) · China (2) · South Korea (2) · Australia (1) · Canada (1) · Ireland (1)
Herzog Thomas, Professor (1) · Lin Shen, Director (1) · Yong Yue, MD (1)
2014 (1)